Regulatory and neurotrophic peptides studied for cognition, stress resilience, sleep, and neuroprotection — many with most of their evidence outside large Western trials. Read each mechanism and its evidence base.
Start with the fundamentals before comparing compounds.
9 compounds in this research area. Each links to a full profile, dosing chart, and sourcing.
Synthetic heptapeptide (tuftsin analog)
A synthetic analog of the immunomodulatory peptide tuftsin, developed in Russia and studied for anxiolytic (anti-anxiety) and cognitive effects, often administered intranasally in research.
Synthetic ACTH(4-10) fragment analog
A synthetic peptide derived from a fragment of ACTH, developed in Russia and studied for nootropic and neuroprotective effects, typically administered intranasally in research.
Nonapeptide
Delta Sleep-Inducing Peptide, a nonapeptide first isolated in connection with sleep regulation. Its effects in humans remain poorly characterized and inconsistent.
Porcine brain-derived neuropeptide preparation
A neurotrophic preparation of low-molecular-weight peptides and amino acids derived from porcine brain tissue, used in several countries for neurological conditions but not FDA-approved.
Nonapeptide neurohypophyseal hormone (9-amino-acid cyclic peptide)
Oxytocin is an endogenous nine-amino-acid neuropeptide produced in the hypothalamus and released from the posterior pituitary. The injectable form (Pitocin/Syntocinon) is FDA-approved for labor induction and postpartum use, while intranasal oxytocin is widely researched for social bonding, trust, and anxiety.
Angiotensin IV-derived oligopeptide analog (HGF/c-Met potentiator)
Dihexa is a small angiotensin IV-derived peptide analog developed as a candidate for cognitive disorders. In preclinical work it is reported to potentiate hepatocyte growth factor (HGF) signaling at the c-Met receptor and to promote synaptogenesis. Human data are essentially absent; it is preclinical/research-only.
Ciliary neurotrophic factor (CNTF)-derived neurogenic peptide (adamantylated small-peptide derivative)
P21 (P021) is a small peptidergic compound derived from an active region of ciliary neurotrophic factor (CNTF), chemically modified (adamantylation) for stability and brain penetration. In preclinical models it is reported to enhance neurogenesis and BDNF signaling and to reduce tau pathology. It is preclinical/research-only.
Short peptide bioregulator (tripeptide)
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) from the Khavinson short-peptide bioregulator program, studied for neuroprotective and cognitive effects. Almost all supporting evidence comes from a single Russian research lineage, and it is not approved; independent human data are very limited.
Dipeptide-derived nootropic (small molecule, oral)
Noopept is a synthetic dipeptide-derived nootropic (N-phenylacetyl-L-prolylglycine ethyl ester) developed in Russia and taken orally, not by injection. It is a prescription nootropic in Russia and sold elsewhere as a supplement, but it is not FDA-approved and robust independent clinical evidence is limited.
Educational summary only. Dosing figures describe how these compounds appear in the research literature and research-community references — they are not a personal treatment plan or a recommendation for human use. For laboratory research use only.
